ABM Industries enters the final stretch before its June 5 earnings with short sellers quietly unwinding — a notable reversal from the aggressive build that defined early April.
The most striking data point this week is not where short interest is, but where it came from. Short interest peaked near 3.7% of the free float on April 3, the highest level of the past month, as tariff anxiety gripped the broader market. It has since fallen 23% in a month to 2.7% of float — a meaningful retreat that signals bears have taken profit or stepped aside. The borrow market reflects the same ease: cost to borrow is a negligible 0.48% annualised, and availability remains generous, with the lending pool far from strained. The 52-week peak for availability usage was 7.3% — today's reading of 2.98% is less than half that level, meaning there is ample room for new shorts to enter if the narrative sours again.
Options positioning reinforces the less defensive tone. Call interest has moved to the front — the put/call ratio has dropped to 0.65, almost two standard deviations below its 20-day average of 0.73. That is the most bullish PCR reading in weeks and stands in contrast to the hedging posture that prevailed through most of April. The shift is consistent with the price action: ABM has recovered around 8% from its early-April lows, closing at $40.44.
The Street remains cautious, though the picture is not uniformly negative. The analyst cluster is dominated by Hold ratings — five of six active recommendations sit there — with a consensus pointing to meaningful upside from current levels toward targets in the mid-$40s to low $50s. All the notable moves came in mid-March, when UBS, Truist, and Baird each trimmed targets following a sharp post-earnings selloff, while Maxim Group moved against the tide with an upgrade to Buy. The bear case centres on the company's ongoing ERP transition: EBITDA conversion collapsed to -6% last quarter from 54% the prior period, free cash flow turned negative, and DSOs stretched as billing systems strained under the rollout. Bulls counter that transformation costs from the ELEVATE initiative should ease in fiscal 2026-27, unlocking FCF recovery and a re-rating toward long-term valuation averages. On multiples, ABM trades on a P/E of roughly 10x and EV/EBITDA near 7x — undemanding for a business with stable, recurring revenues, though the sub-17th-percentile reading on forward EPS growth confirms the Street is not pricing in any near-term acceleration.
One ownership angle worth noting is Pzena Investment Management's addition of 351,000 shares in Q1, and Invesco's addition of 517,000 — two of the larger institutional moves in recent filings. Both are value-oriented managers, and their buying at prices above today's level lends some floor to the thesis, even as the stock trades roughly 10-20% below the range at which they built. The insider picture is less constructive: the COO sold around $1.8 million worth of stock in January and February, and the CEO sold $680,000 on January 9. Net insider activity over the 90-day window shows positive share count largely from non-cash awards, not open-market buying.
The last earnings print on March 10 produced a 5.6% one-day drop and an 11.8% decline over five days — the clearest reference point heading into June 5. Whether the ERP disruption has fully cleared, and whether free cash flow has turned the corner, are the questions that will define how the stock behaves on that day.
See the live data behind this article on ORTEX.
Open ABM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
